- Home
- MHUA vs CARM Comparison
MHUA vs CARM Comparison
Compare MHUA & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- CARM
- Stock Information
- Founded
- MHUA 1990
- CARM 2016
- Country
- MHUA China
- CARM United States
- Employees
- MHUA N/A
- CARM N/A
- Industry
- MHUA Medical Specialities
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- CARM Health Care
- Exchange
- MHUA Nasdaq
- CARM Nasdaq
- Market Cap
- MHUA 13.3M
- CARM 12.1M
- IPO Year
- MHUA 2022
- CARM N/A
- Fundamental
- Price
- MHUA $0.38
- CARM $0.27
- Analyst Decision
- MHUA
- CARM Hold
- Analyst Count
- MHUA 0
- CARM 5
- Target Price
- MHUA N/A
- CARM $0.90
- AVG Volume (30 Days)
- MHUA 135.7K
- CARM 1.2M
- Earning Date
- MHUA 09-19-2025
- CARM 11-06-2025
- Dividend Yield
- MHUA N/A
- CARM N/A
- EPS Growth
- MHUA N/A
- CARM N/A
- EPS
- MHUA 0.29
- CARM N/A
- Revenue
- MHUA $89,547,563.00
- CARM $10,767,000.00
- Revenue This Year
- MHUA N/A
- CARM N/A
- Revenue Next Year
- MHUA N/A
- CARM N/A
- P/E Ratio
- MHUA $1.28
- CARM N/A
- Revenue Growth
- MHUA N/A
- CARM N/A
- 52 Week Low
- MHUA $0.25
- CARM $0.14
- 52 Week High
- MHUA $1.17
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- MHUA N/A
- CARM 45.55
- Support Level
- MHUA N/A
- CARM $0.24
- Resistance Level
- MHUA N/A
- CARM $0.27
- Average True Range (ATR)
- MHUA 0.00
- CARM 0.03
- MACD
- MHUA 0.00
- CARM -0.00
- Stochastic Oscillator
- MHUA 0.00
- CARM 44.15
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.